NO330509B1 - Anvendelse av en COX-2-inhibitor for fremstilling av et medikament, produkt, farmasoytisk blanding samt anvendelse derav. - Google Patents

Anvendelse av en COX-2-inhibitor for fremstilling av et medikament, produkt, farmasoytisk blanding samt anvendelse derav. Download PDF

Info

Publication number: NO330509B1
Authority: NO; Norway
Prior art keywords: cox; cells; mice; inhibitor; maids
Prior art date: 2000-07-20

Application number

NO20030276A

Other languages

English (en)

Norwegian (no)

Other versions

NO20030276L (no

NO20030276D0 (no

Inventor

Jo Klaveness

Michel Moutschen

Souad Mouni-Piette

Christian Carl Johansson

Kjetil Tasken

Einar Martin Aandahl

Pal Aukrust

Stig S Froland

Vidar Hansson

Original Assignee

Lauras As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-20

Filing date

2003-01-20

Publication date

2011-05-09

2000-07-20 Priority claimed from GB0017908A external-priority patent/GB0017908D0/en

2001-04-19 Priority claimed from GB0109648A external-priority patent/GB0109648D0/en

2003-01-20 Application filed by Lauras As filed Critical Lauras As

2003-01-20 Publication of NO20030276D0 publication Critical patent/NO20030276D0/no

2003-03-18 Publication of NO20030276L publication Critical patent/NO20030276L/no

2011-05-09 Publication of NO330509B1 publication Critical patent/NO330509B1/no

Links

229940111134 coxibs Drugs 0.000 title claims description 60
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title claims description 60
239000003814 drug Substances 0.000 title claims description 27
229940079593 drug Drugs 0.000 title claims description 26
238000002360 preparation method Methods 0.000 title claims description 11
239000008194 pharmaceutical composition Substances 0.000 title description 4
239000000047 product Substances 0.000 title description 4
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 66
238000011282 treatment Methods 0.000 claims description 41
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 33
229960000371 rofecoxib Drugs 0.000 claims description 32
238000012360 testing method Methods 0.000 claims description 28
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 27
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 26
229960000590 celecoxib Drugs 0.000 claims description 25
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 18
239000013543 active substance Substances 0.000 claims description 17
230000002265 prevention Effects 0.000 claims description 17
208000030507 AIDS Diseases 0.000 claims description 15
241000700605 Viruses Species 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 15
241001465754 Metazoa Species 0.000 claims description 12
125000000217 alkyl group Chemical group 0.000 claims description 12
125000005843 halogen group Chemical group 0.000 claims description 8
125000003118 aryl group Chemical group 0.000 claims description 7
125000004429 atom Chemical group 0.000 claims description 6
JHBIMJKLBUMNAU-UHFFFAOYSA-N SC-58125 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 JHBIMJKLBUMNAU-UHFFFAOYSA-N 0.000 claims description 5
125000002252 acyl group Chemical group 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
125000002541 furyl group Chemical group 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
125000003226 pyrazolyl group Chemical group 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
125000000547 substituted alkyl group Chemical group 0.000 claims description 4
125000001544 thienyl group Chemical group 0.000 claims description 4
NXERGIJHYVUXHM-UHFFFAOYSA-N 3-(3-fluorophenyl)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CC1(C)OC(=O)C(C=2C=C(F)C=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 NXERGIJHYVUXHM-UHFFFAOYSA-N 0.000 claims description 3
INRQTVDUZFESAO-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-3-(4-methylsulfonylphenyl)-2h-furan-5-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=C(F)C(F)=CC=2)C(=O)OC1 INRQTVDUZFESAO-UHFFFAOYSA-N 0.000 claims description 3
AJFTZWGGHJXZOB-UHFFFAOYSA-N DuP 697 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)SC(Br)=C1 AJFTZWGGHJXZOB-UHFFFAOYSA-N 0.000 claims description 3
125000004122 cyclic group Chemical group 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 2
125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
125000000524 functional group Chemical group 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000002883 imidazolyl group Chemical group 0.000 claims description 2
125000001786 isothiazolyl group Chemical group 0.000 claims description 2
125000000842 isoxazolyl group Chemical group 0.000 claims description 2
125000002971 oxazolyl group Chemical group 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
125000000168 pyrrolyl group Chemical group 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
241000699670 Mus sp. Species 0.000 description 118
210000001744 T-lymphocyte Anatomy 0.000 description 92
210000004027 cell Anatomy 0.000 description 90
208000003434 Murine Acquired Immunodeficiency Syndrome Diseases 0.000 description 69
108010037462 Cyclooxygenase 2 Proteins 0.000 description 67
230000000694 effects Effects 0.000 description 66
210000001165 lymph node Anatomy 0.000 description 56
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 44
230000035755 proliferation Effects 0.000 description 34
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 31
150000001875 compounds Chemical class 0.000 description 31
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 30
229960002986 dinoprostone Drugs 0.000 description 28
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 28
230000001965 increasing effect Effects 0.000 description 27
238000000034 method Methods 0.000 description 26
230000036737 immune function Effects 0.000 description 23
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 22
229960000905 indomethacin Drugs 0.000 description 22
230000005764 inhibitory process Effects 0.000 description 22
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 21
210000003719 b-lymphocyte Anatomy 0.000 description 20
229960001929 meloxicam Drugs 0.000 description 20
230000006052 T cell proliferation Effects 0.000 description 19
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
238000001727 in vivo Methods 0.000 description 19
239000002953 phosphate buffered saline Substances 0.000 description 19
208000015181 infectious disease Diseases 0.000 description 18
238000000338 in vitro Methods 0.000 description 17
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 16
241000725303 Human immunodeficiency virus Species 0.000 description 16
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 13
102100022338 Integrin alpha-M Human genes 0.000 description 13
239000005557 antagonist Substances 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
210000004698 lymphocyte Anatomy 0.000 description 12
229940104230 thymidine Drugs 0.000 description 12
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 11
239000003112 inhibitor Substances 0.000 description 10
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 9
229940124638 COX inhibitor Drugs 0.000 description 9
208000029462 Immunodeficiency disease Diseases 0.000 description 9
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 9
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 9
230000004913 activation Effects 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
230000028993 immune response Effects 0.000 description 9
230000008685 targeting Effects 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
108091000080 Phosphotransferase Proteins 0.000 description 8
230000006044 T cell activation Effects 0.000 description 8
230000004064 dysfunction Effects 0.000 description 8
102000020233 phosphotransferase Human genes 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
208000031886 HIV Infections Diseases 0.000 description 7
206010061598 Immunodeficiency Diseases 0.000 description 7
239000011324 bead Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000000284 extract Substances 0.000 description 7
238000009472 formulation Methods 0.000 description 7
230000007813 immunodeficiency Effects 0.000 description 7
230000009696 proliferative response Effects 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
241000283707 Capra Species 0.000 description 6
208000037357 HIV infectious disease Diseases 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
206010003246 arthritis Diseases 0.000 description 6
238000000684 flow cytometry Methods 0.000 description 6
230000006870 function Effects 0.000 description 6
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 6
238000010348 incorporation Methods 0.000 description 6
238000005259 measurement Methods 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
AAZMHPMNAVEBRE-SDBHATRESA-N 8-(4-chlorophenylthio)-cAMP Chemical compound N=1C=2C(N)=NC=NC=2N([C@H]2[C@@H]([C@@H]3OP(O)(=O)OC[C@H]3O2)O)C=1SC1=CC=C(Cl)C=C1 AAZMHPMNAVEBRE-SDBHATRESA-N 0.000 description 5
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
229940095074 cyclic amp Drugs 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000008569 process Effects 0.000 description 5
150000003180 prostaglandins Chemical class 0.000 description 5
239000001397 quillaja saponaria molina bark Substances 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
229930182490 saponin Natural products 0.000 description 5
150000007949 saponins Chemical class 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
RBORURQQJIQWBS-UHFFFAOYSA-N 6-(6-amino-8-bromopurin-9-yl)-2-hydroxy-2-sulfanylidene-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound O1C2COP(O)(=S)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1Br RBORURQQJIQWBS-UHFFFAOYSA-N 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 4
241000219061 Rheum Species 0.000 description 4
230000005867 T cell response Effects 0.000 description 4
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
230000003308 immunostimulating effect Effects 0.000 description 4
238000001802 infusion Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
229920006008 lipopolysaccharide Polymers 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000013389 whole blood assay Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108010037464 Cyclooxygenase 1 Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
241001494479 Pecora Species 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
101150052863 THY1 gene Proteins 0.000 description 3
125000004423 acyloxy group Chemical group 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000011575 calcium Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
229960001259 diclofenac Drugs 0.000 description 3
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000001280 germinal center Anatomy 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
238000003364 immunohistochemistry Methods 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
229940028435 intralipid Drugs 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
108010082683 kemptide Proteins 0.000 description 3
239000000463 material Substances 0.000 description 3
210000005087 mononuclear cell Anatomy 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
229940094443 oxytocics prostaglandins Drugs 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
102000013415 peroxidase activity proteins Human genes 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
238000009521 phase II clinical trial Methods 0.000 description 3
-1 pivaloyloxymethyl Chemical group 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000000527 sonication Methods 0.000 description 3
238000010186 staining Methods 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000026683 transduction Effects 0.000 description 3
238000010361 transduction Methods 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
WIGDGIGALMYEBW-LLINQDLYSA-N 2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIGDGIGALMYEBW-LLINQDLYSA-N 0.000 description 2
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
102100032912 CD44 antigen Human genes 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
101000994505 Drosophila melanogaster cAMP-dependent protein kinase catalytic subunit 1 Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
238000000585 Mann–Whitney U test Methods 0.000 description 2
102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
241000700159 Rattus Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
230000002917 arthritic effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000003710 calcium ionophore Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
239000000975 dye Substances 0.000 description 2
CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000004030 hiv protease inhibitor Substances 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
238000003365 immunocytochemistry Methods 0.000 description 2
229960001438 immunostimulant agent Drugs 0.000 description 2
239000003022 immunostimulating agent Substances 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
239000000178 monomer Substances 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
229960002009 naproxen Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
108010086662 phytohemagglutinin-M Proteins 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
229940127293 prostanoid Drugs 0.000 description 2
150000003814 prostanoids Chemical class 0.000 description 2
238000011002 quantification Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000012552 review Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
238000011295 triple combination therapy Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
BAZGFSKJAVQJJI-CHHCPSLASA-N (5z)-2-amino-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazol-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(\C=C/2C(N=C(N)S\2)=O)=C1 BAZGFSKJAVQJJI-CHHCPSLASA-N 0.000 description 1
FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 1
JSPUCPNQXKTYRO-LWILDLIXSA-N 2-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]benzene-1,4-diol Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C1=CC(O)=CC=C1O JSPUCPNQXKTYRO-LWILDLIXSA-N 0.000 description 1
WIGDGIGALMYEBW-UHFFFAOYSA-N 2-[[2-[[2-[2-[[2-[[2-[(2-amino-4-methylpentanoyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoylamino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(C)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NCC(O)=O WIGDGIGALMYEBW-UHFFFAOYSA-N 0.000 description 1
RPTFKXDBRBKHQU-UHFFFAOYSA-N 4-(2-oxo-3-phenyl-1,3-oxazol-4-yl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=COC(=O)N1C1=CC=CC=C1 RPTFKXDBRBKHQU-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
108010087765 Antipain Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229940123320 Cyclase inhibitor Drugs 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
238000011891 EIA kit Methods 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000941423 Grom virus Species 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
101001135344 Homo sapiens Polypyrimidine tract-binding protein 1 Proteins 0.000 description 1
101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
101100168274 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-3 gene Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
108700020962 Peroxidase Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
102100033073 Polypyrimidine tract-binding protein 1 Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241001510071 Pyrrhocoridae Species 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Chemical group 0.000 description 1
XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
241000364021 Tulsa Species 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000005042 acyloxymethyl group Chemical group 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
210000001552 airway epithelial cell Anatomy 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000006231 alkoxy propyl group Chemical group 0.000 description 1
125000004848 alkoxyethyl group Chemical group 0.000 description 1
125000004849 alkoxymethyl group Chemical group 0.000 description 1
125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
238000011225 antiretroviral therapy Methods 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
TXJPJZWNYUQWCP-UHFFFAOYSA-N avarol Natural products CC1CCC2(C)C(=CCCC2(C)C1(C)Cc3cc(O)ccc3O)C TXJPJZWNYUQWCP-UHFFFAOYSA-N 0.000 description 1
230000009674 basal proliferation Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000009111 cAMP-PKA pathway Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
229960003340 calcium silicate Drugs 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
108010016348 calcium-independent processing protease Proteins 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000005587 carbonate group Chemical group 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000004656 cell transport Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
108010086192 chymostatin Proteins 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000011436 cob Substances 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960005319 delavirdine Drugs 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
229960003804 efavirenz Drugs 0.000 description 1
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
229950002002 emivirine Drugs 0.000 description 1
MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 1
229960004945 etoricoxib Drugs 0.000 description 1
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229950005722 flosulide Drugs 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000005021 gait Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000003304 gavage Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
239000004519 grease Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000005802 health problem Effects 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
229940082061 indomethacin 25 mg Drugs 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229950002252 isoxicam Drugs 0.000 description 1
YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical class COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
229940112801 mobic Drugs 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000002346 musculoskeletal system Anatomy 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
229960000965 nimesulide Drugs 0.000 description 1
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
239000002353 niosome Substances 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
RXBWRFDZXRAEJT-SZNOJMITSA-N palinavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)CN1[C@@H](C[C@@H](CC1)OCC=1C=CN=CC=1)C(=O)NC(C)(C)C)C1=CC=CC=C1 RXBWRFDZXRAEJT-SZNOJMITSA-N 0.000 description 1
229950006460 palinavir Drugs 0.000 description 1
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
102000017953 prostanoid receptors Human genes 0.000 description 1
108050007059 prostanoid receptors Proteins 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
230000019908 regulation of T cell activation Effects 0.000 description 1
230000012121 regulation of immune response Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229960001852 saquinavir Drugs 0.000 description 1
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
229960001203 stavudine Drugs 0.000 description 1
239000012058 sterile packaged powder Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000010648 susceptibility to HIV infection Diseases 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000010809 targeting technique Methods 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
229960003676 tenidap Drugs 0.000 description 1
LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
229960002871 tenoxicam Drugs 0.000 description 1
WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
125000004417 unsaturated alkyl group Chemical group 0.000 description 1
229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
229960002004 valdecoxib Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229940087652 vioxx Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20030276A 2000-07-20 2003-01-20 Anvendelse av en COX-2-inhibitor for fremstilling av et medikament, produkt, farmasoytisk blanding samt anvendelse derav. NO330509B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0017908A GB0017908D0 (en)	2000-07-20	2000-07-20	Method
GB0109648A GB0109648D0 (en)	2001-04-19	2001-04-19	Method
PCT/GB2001/003284 WO2002007721A2 (en)	2000-07-20	2001-07-20	Use of cox-2 inhibitors for preventing immunodeficiency

Publications (3)

Publication Number	Publication Date
NO20030276D0 NO20030276D0 (no)	2003-01-20
NO20030276L NO20030276L (no)	2003-03-18
NO330509B1 true NO330509B1 (no)	2011-05-09

Family

ID=26244695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20030276A NO330509B1 (no)	2000-07-20	2003-01-20	Anvendelse av en COX-2-inhibitor for fremstilling av et medikament, produkt, farmasoytisk blanding samt anvendelse derav.

Country Status (22)

Country	Link
US (1)	US7790738B2 (el)
EP (1)	EP1303265B1 (el)
JP (1)	JP2004510705A (el)
CN (1)	CN100488500C (el)
AP (1)	AP1780A (el)
AT (1)	ATE366569T1 (el)
AU (1)	AU7090201A (el)
CA (1)	CA2415577C (el)
CY (1)	CY1107069T1 (el)
CZ (1)	CZ302448B6 (el)
DE (1)	DE60129330T2 (el)
DK (1)	DK1303265T3 (el)
ES (1)	ES2290157T3 (el)
HK (1)	HK1055087A1 (el)
HU (1)	HUP0302068A3 (el)
NO (1)	NO330509B1 (el)
NZ (1)	NZ524252A (el)
OA (1)	OA12339A (el)
PL (1)	PL359556A1 (el)
PT (1)	PT1303265E (el)
RU (1)	RU2303452C2 (el)
WO (1)	WO2002007721A2 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003530437A (ja) *	2000-04-13	2003-10-14	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	Ａβ４２低下物質
HUP0302068A3 (en)	2000-07-20	2005-05-30	Lauras As	Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
EP1603548A4 (en) *	2003-02-05	2007-10-10	Myriad Genetics Inc	COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
KR20060040676A (ko) *	2003-07-11	2006-05-10	미리어드 제네틱스, 인크.	알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
WO2005013902A2 (en) *	2003-08-04	2005-02-17	Mayo Foundation For Medical Education And Research	Methods and compositions for inhibiting the proliferation of prostate cancer cells
WO2006001877A2 (en) *	2004-04-13	2006-01-05	Myriad Genetics, Inc.	Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
MXPA06012165A (es) *	2004-04-29	2007-01-17	Keystone Retaining Wall System	Chapas para muros, muros de contencion y similares.
WO2006020850A2 (en) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Pharmaceutical composition and method for treating neurodegenerative disorders
WO2007014124A2 (en) *	2005-07-22	2007-02-01	Myriad Genetics, Inc.	High drug load formulations and dosage forms
WO2007013997A2 (en) *	2005-07-22	2007-02-01	H. Lee Moffitt Cancer Center And Research Institute	Inhibition of the raf/mek/p-erk pathway for treating cancer
US20070281927A1 (en) *	2006-06-06	2007-12-06	Shanthakumar Tyavanagimatt	Anti-inflammatory and analgesic compositions and related methods
US20080033045A1 (en) *	2006-07-07	2008-02-07	Myriad Genetics, Incorporated	Treatment of psychiatric disorders
EP2481420B1 (en)	2006-12-15	2019-02-20	Boehringer Ingelheim Vetmedica, Inc.	Single dose anti-PCV2 pig vaccine
EP1941903A1 (en)	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxis and treatment of PRDC
EP1958644A1 (en)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prevention and treatment of sub-clinical pcvd
IN2014CH00396A (el) *	2013-02-05	2015-04-03	Nitto Denko Corp
CN108849912B (zh) *	2018-07-26	2020-06-30	河南省农业科学院植物保护研究所	1,5-二芳基-3-三氟甲基吡唑类化合物在防治农业真菌病害中的应用

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1325832A (en) *		1919-12-23		Beak-axle mounting eor tractors
US2011239A (en) *	1933-07-31	1935-08-13	Packard Motor Car Co	Motor vehicle
US2163981A (en) *	1938-12-06	1939-06-27	Norman E Lawrence	Rear wheel suspension for motor vehicles
US2606036A (en) *	1945-11-01	1952-08-05	Six Wheels Inc	Mounting for wheel brake operating mechanism
US2635896A (en) *	1949-07-26	1953-04-21	Brown Trailers Inc	Vehicle wheel suspension
US2877010A (en) *	1956-10-16	1959-03-10	Gouirand Rene	Pneumatic suspension for motor vehicles
US2913252A (en) *	1957-08-02	1959-11-17	Pacific Car & Foundry Co	Vehicle suspension using air spring
NL232523A (el) *	1957-11-27
NL302468A (el) *	1961-05-11
US3434707A (en) *	1966-06-02	1969-03-25	John E Raidel	Suspensions
FR1573973A (el) *	1968-03-28	1969-07-11
US3547215A (en) *	1968-06-07	1970-12-15	Neway Equipment Co	Automotive vehicle suspension structure
US3630541A (en) *	1970-06-11	1971-12-28	Int Harvester Co	Vehicle axle suspension
US3707298A (en) *	1970-10-06	1972-12-26	Lear Siegler Inc	Suspension structure for land vehicles
US3785673A (en) *	1971-09-20	1974-01-15	Western Unit Corp	Preloaded spring beam and method employed alone or in combination with air bellows spring
US3771812A (en) *	1972-04-25	1973-11-13	Lear Siegler Inc	Air suspension with improved axle lifting structure
US3961826A (en) *	1975-03-06	1976-06-08	American Carrier Equipment, Inc.	Suspension unit
DE2523121C2 (de) *	1975-05-24	1984-06-20	Volkswagenwerk Ag, 3180 Wolfsburg	Hinterachsaufhängung für Kraftfahrzeuge
US4027898A (en) *	1976-04-07	1977-06-07	Southwest Wheel And Manufacturing Company	Level load leaf spring drop axle
US4065153A (en) *	1976-08-19	1977-12-27	United States Steel Corporation	Vehicle wheel suspension assembly
US4174855A (en) *	1977-01-13	1979-11-20	Turner Quick-Lift Corporation	Wheeled vehicle axle suspension system
US4352509A (en) *	1978-01-18	1982-10-05	H. Neil Paton	Damped rubber tired vehicle suspension
US4293145A (en) *	1978-02-28	1981-10-06	Taylor Glenn E	Auxiliary lift axle wheel assembly
US4166640B1 (en) *	1978-04-14	1994-03-22	Boler Company Inc	Axle suspension for wheeled vehicles
US4371190A (en) *	1980-01-28	1983-02-01	Turner Quick-Lift Corporation	Axle suspension system
US4310171A (en) *	1980-06-11	1982-01-12	General Motors Corporation	Vehicle axle attachment
US4415179A (en) *	1981-04-15	1983-11-15	Marinelli Joseph A	Axle and air bag suspension
US4529224A (en) *	1981-05-21	1985-07-16	Raidel John E	Wide base air spring suspension assembly
US4537420A (en) *	1981-07-28	1985-08-27	Nissan Motor Company, Limited	Swing-arm-type suspension with a lateral rod for an automotive vehicle
US4427213A (en) *	1982-01-21	1984-01-24	Raidel Jr John E	Vehicle suspension with rigid torque beam
US4494771A (en) *	1982-01-21	1985-01-22	Raidel John E	Suspension system with U-joint mounted load carrying torque arm
US4504080A (en) *	1983-05-16	1985-03-12	Turner Quick-Lift Corporation	Leaf spring lift axle suspension system
US4541643A (en) *	1983-06-27	1985-09-17	Ivan Pavincic	Two wheel skating device
US4566719A (en) *	1984-02-17	1986-01-28	Turner Quick Lift Corporation	Spaced axle-to-beam connection for suspension of the rigid beam type
US4693486A (en) *	1986-04-09	1987-09-15	Lear Siegler, Inc.	Trailing arm suspension with wrapper compression axle mounting
US4691937A (en) *	1986-05-19	1987-09-08	Raidel John E	Vehicle suspension assembly
US5002305A (en) *	1987-02-04	1991-03-26	Raidel John E	Vehicle suspension system with standardized torque beam and special monopivot bushing assembly
US4902035A (en) *	1987-02-04	1990-02-20	Raidel John E	Suspension system with axle seat removable from universal torque beam
US4763923A (en) *	1987-03-02	1988-08-16	Raidel John E	Suspension assembly with air spring and self contained air lift spring
US4878691A (en) *	1988-03-23	1989-11-07	Dbx Corporation	Trailer suspension apparatus
GB8814057D0 (en) *	1988-06-14	1988-07-20	Lundbeck & Co As H	New enantiomers & their isolation
US4943081A (en) *	1989-02-10	1990-07-24	Rancho Industries, Inc.	Vehicle suspension assembly
DE3913697A1 (de) *	1989-04-26	1990-10-31	Bergische Achsen Kotz Soehne	Achsaggregat
US4991868A (en) *	1989-12-19	1991-02-12	The Boler Company	Vehicle suspension beam pivot connection
US5504108A (en)	1990-01-12	1996-04-02	The Ohio State University Research Foundation	Optically pure 4-aryl-2-hydroxytetronic acids
US5058916A (en) *	1990-06-18	1991-10-22	Lear Siegler Truck Products Corp.	Apparatus for providing additional lift in a retractable suspension
US5037126A (en) *	1990-09-07	1991-08-06	The Boler Company	Lightweight beam suspension system
JPH06504779A (ja)	1990-12-13	1994-06-02	スミスクライン・ビーチャム・コーポレイション	新規ｃｓａｉｄｓ
US5112078A (en) *	1990-12-21	1992-05-12	Neway Corp.	Axle mounting assembly
US5127668A (en) *	1991-01-24	1992-07-07	Raidel John E	Torque beam with clamped mono-pivot bushing and flexible axle seat
US5203585A (en) *	1991-07-12	1993-04-20	Neway Corp.	Split-beam suspension system
US5171036A (en) *	1991-08-27	1992-12-15	The Boler Company	Rebound strap
US5240929A (en)	1992-08-03	1993-08-31	Warner-Lambert Company	2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
AU666572B2 (en) *	1992-10-19	1996-02-15	Hendrickson International Corporation	Axle suspension systems
ES2089736T3 (es)	1992-10-28	1996-10-01	Shionogi & Co	Derivados de bencilideno.
JP3465277B2 (ja) *	1992-11-26	2003-11-10	トヨタ自動車株式会社	アンダボデー構造
US5604260A (en)	1992-12-11	1997-02-18	Merck Frosst Canada Inc.	5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
CA2293952A1 (en)	1993-01-15	1994-07-21	David B. Reitz	Preparation of esters and analogs thereof
US5409944A (en)	1993-03-12	1995-04-25	Merck Frosst Canada, Inc.	Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2163081C (en)	1993-05-18	2000-03-14	Myeong-Hee Yu	Thermoresistant alpha-1-antitrypsin mutein
US5380738A (en)	1993-05-21	1995-01-10	Monsanto Company	2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
DE69433087T2 (de) *	1993-06-11	2004-06-09	Coulter International Corp., Miami	Anti-cd3-antikörper-aminodextran-konjugate zur induktion der t-zellen-aktivierung und vermehrung
US5474995A (en) *	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5375871A (en) *	1993-07-02	1994-12-27	Ridewell Corporation	Vehicle suspension system comprising a wide base beam and axle shell
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
US5344991A (en) *	1993-10-29	1994-09-06	G.D. Searle & Co.	1,2 diarylcyclopentenyl compounds for the treatment of inflammation
DK0731795T3 (da)	1993-11-30	2000-05-15	Searle & Co	Substituerede pyrazolylbenzensulfonamider til behandling af inflammation
US5475018A (en) *	1993-11-30	1995-12-12	G. D. Searle & Co.	1,5-diphenyl pyrazole compounds for treatment of inflammation
US5434178A (en) *	1993-11-30	1995-07-18	G.D. Searle & Co.	1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5403031A (en) *	1993-12-08	1995-04-04	The Boler Company	Parallelogram lift axle suspension system with a control for axle caster adjustment
AU692231B2 (en)	1994-02-10	1998-06-04	G.D. Searle & Co.	Substituted spiro compounds for the treatment of inflammation
US5393790A (en) *	1994-02-10	1995-02-28	G.D. Searle & Co.	Substituted spiro compounds for the treatment of inflammation
US5639110A (en) *	1994-04-14	1997-06-17	Nai Neway, Inc.	Trailing arm suspension
US5643960A (en) *	1994-04-15	1997-07-01	Duke University	Method of delaying onset of alzheimer's disease symptoms
US5486534A (en)	1994-07-21	1996-01-23	G. D. Searle & Co.	3,4-substituted pyrazoles for the treatment of inflammation
AU3201095A (en)	1994-07-27	1996-02-22	G.D. Searle & Co.	Substituted thiazoles for the treatment of inflammation
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en)	1994-07-28	1997-04-01	Gd Searle & Co	1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
GB9415529D0 (en)	1994-08-01	1994-09-21	Wellcome Found	Phenyl xanthine derivatives
US5464245A (en) *	1994-08-08	1995-11-07	The Boler Company	Suspension for light duty trucks
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
EP0782855B1 (en) *	1994-10-05	2001-09-12	Helsinn Healthcare S.A.	Nimesulide for external use
US5739166A (en)	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
DE4442560A1 (de)	1994-11-30	1996-06-05	Basf Ag	Iminooxybenzylcrotonsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung
US5603724A (en)	1995-02-13	1997-02-18	Tnco, Inc.	Suction punch
CA2212836C (en)	1995-02-13	2003-08-12	G.D. Searle & Co.	Substituted isoxazoles for the treatment of inflammation
CZ313397A3 (cs)	1995-04-04	1998-03-18	Glaxo Group Limited	Imidazo/1,2a/pyridinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
US5720489A (en) *	1995-05-17	1998-02-24	The Boler Company	Movable subframe for tractor-trailers
US5510368A (en) *	1995-05-22	1996-04-23	Merck Frosst Canada, Inc.	N-benzyl-3-indoleacetic acids as antiinflammatory drugs
GB9514518D0 (en)	1995-07-15	1995-09-13	Sod Conseils Rech Applic	Guanidine salt inhibitors of NO synthase and cyclooxygenase
US5785345A (en) *	1995-10-16	1998-07-28	The Boler Company	Means for and method of controlling frame rise in vehicle suspensions
ZA97175B (en) *	1996-01-11	1997-11-04	Smithkline Beecham Corp	Novel substituted imidazole compounds.
JP2001506574A (ja) *	1996-02-13	2001-05-22	ジー．ディー．サールアンドカンパニー	シクロオキシゲナーゼ―２阻害剤およびロイコトリエンａ４ヒドロラーゼ阻害剤を含有する免疫抑制効果をもつ配合物
SK285353B6 (sk)	1996-04-12	2006-11-03	G. D. Searle & Co.	Substituované benzénsulfónamidy ako proliečivá COX-2 inhibítorov, farmaceutická kompozícia a spôsobich prípravy a použitia
US5690353A (en) *	1996-05-09	1997-11-25	Suspensions Incorporated	Suspension system with improved beam
US5950971A (en) *	1996-06-28	1999-09-14	The Boler Company	Assembly for and method of mounting a suspension member to an axle housing
CA2259598A1 (en)	1996-07-09	1998-01-15	Smithkline Beecham S.P.A.	Indole derivatives for the treatment of osteoporosis
WO1998006715A1 (en)	1996-08-09	1998-02-19	Smithkline Beecham Corporation	Novel piperazine containing compounds
US6005000A (en)	1996-08-22	1999-12-21	Oxis International, Inc.	5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
US5996981A (en) *	1996-08-28	1999-12-07	The Boler Company	Reduced size bushing for beam-type axle suspension system
DE29616257U1 (de) *	1996-09-19	1996-11-07	Otto Sauer Achsenfabrik Keilberg, 63856 Bessenbach	Aufhängung für luftgefederte Fahrzeugradachse
ITMI962356A1 (it)	1996-11-13	1998-05-13	Uni Degli Studi Di Brescia D I	Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
US5921570A (en) *	1996-11-21	1999-07-13	The Boler Company	Weld-on axle bracket with U-bolt connection
JP4167733B2 (ja)	1996-12-16	2008-10-22	花王株式会社	ＮＦ−κＢ活性化抑制剤
US5810377A (en) *	1997-01-21	1998-09-22	The Boler Company	Fabricated steer axle
ES2201466T3 (es)	1997-03-14	2004-03-16	MERCK FROSST CANADA & CO.	`(metilsulfonil)fenil-2-(5h)-furanonas con enlace con oxigeno como inhibidores de cox-2`.
DE69825154T2 (de)	1997-03-14	2005-07-21	Merck Frosst Canada & Co, Kirkland	Pyridazinone als inhibitoren von cyclooxygenase-2
CA2285567A1 (en)	1997-04-02	1998-10-08	Merck Frosst Canada & Co.	Alpha-methylene gamma lactones as selective cyclooxygenase-2 inhibitors
SE9701304D0 (sv)	1997-04-09	1997-04-09	Astra Pharma Prod	Compounds
TW492959B (en)	1997-04-18	2002-07-01	Merck & Co Inc	Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
US5944339A (en) *	1997-05-06	1999-08-31	Meritor Heavy Vehicle Systems, Llc	Integrated axle suspension anti-roll arrangement for push-pull suspension
US6073946A (en) *	1997-07-16	2000-06-13	Neway Anchorlok International, Inc.	Trailing arm suspension
US5988672A (en) *	1997-08-11	1999-11-23	Meritor Heavy Vehicle Suspension Systems, Inc.	Suspension system with integral box beam
US5887881A (en) *	1997-08-11	1999-03-30	The Boler Company.	Leaf spring attachment member
CA2303152A1 (en)	1997-09-05	1999-03-18	Glaxo Group Limited	2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
AU741755B2 (en)	1997-09-12	2001-12-06	Merck Frosst Canada Ltd.	2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
CA2301590C (en)	1997-09-12	2007-05-01	Merck Frosst Canada & Co.	2-aminopyridines as inhibitors of cyclooxygenase-2
US6039336A (en) *	1997-09-19	2000-03-21	Otto Sauer Achsenfabrik Keilberg	Vehicle axle suspension assembly
JP3516658B2 (ja)	1997-09-24	2004-04-05	メルクエンドカムパニーインコーポレーテッド	Ｃｏｘ−２のインヒビターとして有用な３−アリールオキシ，４−アリールフラン−２−オンの製造方法
AR015938A1 (es)	1997-09-25	2001-05-30	Merck Sharp & Dohme	Procedimiento para preparar diaril piridinas utiles como inhibidores cox-2 y compuesto intermediario
WO1999020110A1 (en)	1997-10-22	1999-04-29	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease
JP2001521932A (ja)	1997-10-30	2001-11-13	メルクフロストカナダアンドカンパニー	選択的シクロオキシゲナーゼ−２−阻害剤としてのジアリール−５−アルキル−５−メチル−２（５ｈ）−フラノン
US6025353A (en) *	1997-11-19	2000-02-15	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US5938221A (en) *	1997-12-08	1999-08-17	The Boler Company	Tapered convolute leaf spring for truck suspensions
JP2002515891A (ja)	1997-12-19	2002-05-28	スミスクライン・ビーチャム・コーポレイション	新規なピペリジン含有化合物
MXPA00012632A (es) *	1998-07-02	2002-07-02	Boler Co	Sistema de eje/suspension de brazo de remolque.
US6420403B1 (en) *	1998-10-29	2002-07-16	Edwin J. Iwanowicz	Inhibitors of IMPDH enzyme
US6209895B1 (en) *	1998-12-03	2001-04-03	Reyco Industries, Inc.	Axle suspension system for a wheeled vehicle
WO2000040243A1 (en) *	1999-01-08	2000-07-13	Smithkline Beecham Corporation	Novel compounds
US6123349A (en) *	1999-04-09	2000-09-26	Standen's Limited	Vehicle air suspension system
US20030138399A1 (en) *	1999-05-14	2003-07-24	Anton Peter A.	Anti-inflammatory therapy for inflammatory mediated infection
JP2002544210A (ja)	1999-05-14	2002-12-24	ザリージェンツオブザユニバーシティオブカリフォルニア	炎症で仲介される感染症に対する抗炎症性治療方法
OA11831A (en) *	1999-12-08	2005-08-23	Pharmacia Corp	Polymorphic crystalline forms of celecoxib.
US6264231B1 (en) *	2000-03-20	2001-07-24	The Boler Company	Axle suspension connection
EP1265762B1 (en) *	2000-03-22	2005-10-26	Hendrickson International Corporation	Aluminum frame hanger for axle/suspension systems
US6306842B1 (en) *	2000-06-02	2001-10-23	Medinox, Inc.	Protected forms of a combination of pharmacologically active agents and uses therefor
HUP0302068A3 (en)	2000-07-20	2005-05-30	Lauras As	Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
GB0021716D0 (en) *	2000-09-05	2000-10-18	Meritor Heavy Vehicle Sys Ltd	Vehicle suspension axle wrap
US7007960B2 (en) *	2002-02-01	2006-03-07	Watson & Chalin Manufacturing, Inc.	Suspension system having reduced stress axle connection

2001
- 2001-07-20 HU HU0302068A patent/HUP0302068A3/hu unknown
- 2001-07-20 AP APAP/P/2003/002719A patent/AP1780A/en active
- 2001-07-20 CA CA2415577A patent/CA2415577C/en not_active Expired - Fee Related
- 2001-07-20 WO PCT/GB2001/003284 patent/WO2002007721A2/en active IP Right Grant
- 2001-07-20 AT AT01949787T patent/ATE366569T1/de not_active IP Right Cessation
- 2001-07-20 AU AU7090201A patent/AU7090201A/xx not_active Withdrawn
- 2001-07-20 CZ CZ20030177A patent/CZ302448B6/cs not_active IP Right Cessation
- 2001-07-20 PL PL01359556A patent/PL359556A1/xx not_active Application Discontinuation
- 2001-07-20 JP JP2002513457A patent/JP2004510705A/ja active Pending
- 2001-07-20 ES ES01949787T patent/ES2290157T3/es not_active Expired - Lifetime
- 2001-07-20 CN CNB018143199A patent/CN100488500C/zh not_active Expired - Fee Related
- 2001-07-20 EP EP01949787A patent/EP1303265B1/en not_active Expired - Lifetime
- 2001-07-20 RU RU2003104981/15A patent/RU2303452C2/ru not_active IP Right Cessation
- 2001-07-20 NZ NZ524252A patent/NZ524252A/en unknown
- 2001-07-20 PT PT01949787T patent/PT1303265E/pt unknown
- 2001-07-20 US US10/333,657 patent/US7790738B2/en not_active Expired - Fee Related
- 2001-07-20 DE DE60129330T patent/DE60129330T2/de not_active Expired - Lifetime
- 2001-07-20 OA OA1200300011A patent/OA12339A/en unknown
- 2001-07-20 DK DK01949787T patent/DK1303265T3/da active
2003
- 2003-01-20 NO NO20030276A patent/NO330509B1/no not_active IP Right Cessation
- 2003-10-15 HK HK03107425A patent/HK1055087A1/xx not_active IP Right Cessation
2007
- 2007-10-08 CY CY20071101278T patent/CY1107069T1/el unknown

Also Published As

Publication number	Publication date
NZ524252A (en)	2004-03-26
ES2290157T3 (es)	2008-02-16
CN100488500C (zh)	2009-05-20
JP2004510705A (ja)	2004-04-08
CN1561204A (zh)	2005-01-05
CA2415577C (en)	2010-10-19
OA12339A (en)	2006-05-15
EP1303265B1 (en)	2007-07-11
DK1303265T3 (da)	2007-11-12
US7790738B2 (en)	2010-09-07
RU2303452C2 (ru)	2007-07-27
ATE366569T1 (de)	2007-08-15
AP1780A (en)	2007-09-26
WO2002007721A3 (en)	2002-04-18
AP2003002719A0 (en)	2003-06-30
WO2002007721A2 (en)	2002-01-31
HUP0302068A3 (en)	2005-05-30
HUP0302068A2 (hu)	2003-11-28
HK1055087A1 (en)	2003-12-24
CA2415577A1 (en)	2002-01-31
US20040082640A1 (en)	2004-04-29
CY1107069T1 (el)	2012-10-24
PT1303265E (pt)	2007-10-09
CZ302448B6 (cs)	2011-05-25
EP1303265A2 (en)	2003-04-23
AU7090201A (en)	2002-02-05
NO20030276L (no)	2003-03-18
DE60129330D1 (de)	2007-08-23
PL359556A1 (en)	2004-08-23
NO20030276D0 (no)	2003-01-20
DE60129330T2 (de)	2008-04-10

Publication	Publication Date	Title
CA2415577C (en)	2010-10-19	Use of cox-2 inhibitors for preventing immunodeficiency
US20030191172A1 (en)	2003-10-09	Method of using cyclooxygenase inhibitors and antimuscarinic agents
CA2348543A1 (en)	2000-05-11	5ht1 receptor agonists and metoclopramide for the treatment of migraine
CN102655859A (zh)	2012-09-05	病毒感染的组合疗法治疗
KR20030087046A (ko)	2003-11-12	요실금 치료에서 선택적 ｃｏｘ-2 억제물질의 용도
US20050026902A1 (en)	2005-02-03	Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
CA2526122A1 (en)	2005-01-06	Compositions for down-regulation of ccr5 expression and methods of use therefor
WO2004093910A1 (ja)	2004-11-04	ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
Rahmouni et al.	2004	Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T-cell dysfunction in mice
AU2001270902B2 (en)	2007-03-08	Use of COX-2 inhibitors for preventing immunodeficiency
JP5579958B2 (ja)	2014-08-27	Ｃｏｘ−２インヒビターを含有する鎮痛及び抗炎症性組成物
ZA200300446B (en)	2004-04-16	Use of cox-2 inhibitors for preventing immunodeficiency.
CA2308323A1 (en)	2000-11-14	5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine
US20030216458A1 (en)	2003-11-20	Combination therapy for the treatment of migraine
CA2312631A1 (en)	2000-12-30	5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
Cheng	2002	Angiotensin II induced inflammation and vascular dysfunction: Role of oxidative stress and cyclooxygenase
AU3253800A (en)	2000-11-16	Combination therapy for the treatment of migraine
Potenza et al.	2002	Endothelial cyclo-oxygenase-1 and-2 differentially affect reactivity of mesenteric vascular bed in portal hypertensive rats
US20140303251A1 (en)	2014-10-09	Methods Of Treating Acute Kidney Injury With Retinoic Acid
BAKER	0	Patent 2526122 Summary
WO2003037373A1 (en)	2003-05-08	Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
JP2006528695A (ja)	2006-12-21	血流量の減少又は中枢神経系の外傷を治療するためのベンゼンスルホンアミド又はメチルスルホニルベンゼン系シクロオキシゲナーゼ−２選択的阻害剤及びコリン作動性作用物質の組成物
EP1915992A1 (en)	2008-04-30	Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
NZ235638A (en)	1997-02-24	The use of indole derivatives for treating interleukin-1 related disorders

Legal Events

Date	Code	Title	Description
2012-02-20	MM1K	Lapsed by not paying the annual fees